Brief: Abbisko Cayman Says Absk011 Hcc Combo Clinical Trial Approved By NMPA
26/09/2023 02:54
Sept 26 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ABSK011 HCC COMBO CLINICAL TRIAL APPROVED BY NMPA
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly